Sign up to save your podcasts
Or
Share From inflammation to action: MPO’s role in chronic disease (14 min)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
From inflammation to action: MPO’s role in chronic disease (14 min)
Inflammation plays a critical role in cardiometabolic diseases, but traditional risk markers like LDL-C and hs-CRP don’t tell the whole story. Myeloperoxidase (MPO), an enzyme linked to oxidative stress and immune activation, may offer a deeper look into hidden cardiovascular and metabolic risk. In this episode, Dr Marc Penn unpacks the new research examining the association between MPO and the risk for chronic kidney disease (CKD) and nonalcoholic fatty liver disease (NAFLD) across atherogenic cardiovascular disease (ASCVD) risk groups and what it might mean for prevention and tailored treatment.
This episode will
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 6/2025
Speaker(s): Maeson Latsko, PhD; Dr Marc Penn
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Kathryn Morales, MS
Additional Resources
Ordering information
MPO ordering information
Quest Diagnostics Clinical Education Center [Link]
References
Iakoubova OA, Haji-Sheikhi F, Louie JZ, et al. Association of MPO levels with cardiometabolic disease stratified by atherosclerotic cardiovascular risk and intensity of therapy in a workforce population. Sci Rep. 2025;15(1):12244. Published 2025 Apr 10. doi:10.1038/s41598-025-89373-7
View all episodes
By Quest DiagnosticsInflammation plays a critical role in cardiometabolic diseases, but traditional risk markers like LDL-C and hs-CRP don’t tell the whole story. Myeloperoxidase (MPO), an enzyme linked to oxidative stress and immune activation, may offer a deeper look into hidden cardiovascular and metabolic risk. In this episode, Dr Marc Penn unpacks the new research examining the association between MPO and the risk for chronic kidney disease (CKD) and nonalcoholic fatty liver disease (NAFLD) across atherogenic cardiovascular disease (ASCVD) risk groups and what it might mean for prevention and tailored treatment.
This episode will
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 6/2025
Speaker(s): Maeson Latsko, PhD; Dr Marc Penn
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Kathryn Morales, MS
Additional Resources
Ordering information
MPO ordering information
Quest Diagnostics Clinical Education Center [Link]
References
Iakoubova OA, Haji-Sheikhi F, Louie JZ, et al. Association of MPO levels with cardiometabolic disease stratified by atherosclerotic cardiovascular risk and intensity of therapy in a workforce population. Sci Rep. 2025;15(1):12244. Published 2025 Apr 10. doi:10.1038/s41598-025-89373-7